CTCX News & Events

Carmell announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launched a new corporate logo while branding for existing marketed products shall remain unchanged.

PMGC (ELAB) announced the closing of the previously announced divestiture of its 100% wholly owned subsidiary Elevai Skincare pursuant to a definitive purchase agreement with Carmell Corporation (CTCX) and reaffirms its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic Divestiture marks a significant milestone in PMGC's journey as a diversified holding company.

Carmell Corporation announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings and Elevai, its wholly owned subsidiary. At the closing of the Acquisition (the "Closing"), the purchase consideration consisted of the following: Approximately $1.1 million of Carmell common stock at a price of $0.8488 per share as follows: 1,149,226 shares of Carmell common stock at Closing, plus; 117,814 shares of Carmell common stock held back by Carmell to secure indemnification obligations of PMGC and Elevai for 12 months after Closing;Approximately $57,000 in cash to be paid by Carmell upon the sale of specified inventory existing as of the Closing.

Carmell Corporation (CTCX) announced that it entered into a definitive purchase agreement with PMGC Holdings (ELAB) and its wholly owned subsidiary, Elevai Skincare, to acquire the assets related to its skincare and haircare business. The purchase consideration for the Acquisition is as follows: Approximately $1.1 million in Carmell common stock at the closing of the Acquisition; Approximately $57,000 in cash upon the sale of specified inventory existing as of the Closing; Contingent earnout consideration consisting of: 5% of net sales from Elevai's existing products paid annually during the 5-year period following the Closing, and a one-time milestone payment of $500,000 if Elevai's hair and scalp products achieve $500,000 in net revenue within 24 months following the Closing; and Carmell's assumption of contractual liabilities and trade payables of Elevai at the Closing. As part of the Acquisition, Carmell expects to acquire the following assets of Elevai: Product portfolio with trailing twelve-month revenue of approximately $2.5 million; Commercial and product development team; Finished and work-in-process inventory of approximately $1.0 million; and Accounts receivable of approximately $0.03 million.